ArticleClinical kidney journal2026
Abstract submissions to the ERA Congress: what they tell us about nephrology's trajectory.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
submission trends to the ERA Congress provide a valuable lens through which to observe the evolution of nephrology research and education. Analysing submissions from 2020 to 2026, we document a marked recovery following the COVID-19 disruption, culminating in a record number of abstracts for the 2026 Congress in Glasgow. Beyond volume, notable shifts have occurred in subject mix, geographic participation and reviewer scoring patterns. Chronic kidney disease and glomerular disorders now dominate submissions, reflecting major scientific advances and changing clinical priorities, while international engagement has broadened substantially. These trends suggest that the ERA Congress has entered a new phase characterised by sustained high activity rather than transient post-pandemic rebound. We discuss the implications for congress programme design, peer review, inclusiveness and future strategic planning, highlighting how abstract data can inform the direction of large scientific meetings and the nephrology community at large.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.